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Background: In peritoneal dialysis (PD), residual renal function (RRF) fundamentally con-
tributes to improved quality of life and patient survival. High glucose and advanced
glycation end-products (AGE) contribute locally to peritoneal and systemically to renal dam-
age. Integrity of podocyte structure and function is of special importance to preserve
RRF. Benfotiamine could counteract the glucose and AGE-mediated toxicity by blocking
hyperglycemia-associated podocyte damage via the pentose-phosphate pathway.
Methods: A human differentiated podocyte cell line was incubated with control solution
(control), 2.5% glucose solution (glucose), and 2.5% peritoneal dialysis fluid (PDF) for 48 h
either±50µM benfotiamine. Podocyte damage and potential benefit of benfotiamine were
analyzed using immunofluorescence, western blot analysis, and a functional migration
assay. For quantitation, a semiquantitative score was used.
Results: When incubating podocytes with benfotiamine, glucose, and PDF-mediated dam-
age was reduced, resulting in lower expression of AGE and intact podocin and ZO-1
localization. The reorganization of the actin cytoskeleton was restored in the presence
of benfotiamine as functional podocyte motility reached control level. Decreased level of
inflammation could be shown as well as reduced podocyte apoptosis.
Conclusion: These data suggest that benfotiamine protects podocytes from glucose
and PDF-mediated dysfunction and damage, in particular, with regard to cytoskeletal
reorganization, motility, inflammation, and podocyte survival.
Keywords: benfotiamine, glucose degradation products, high glucose, peritoneal dialysis, peritoneal dialysis fluids,
podocytes, systemic toxicity
Short summary: It is known that high glucose and advanced gly-
cation end-products (AGE) do not only cause local peritoneal
toxicity but also systemic damage and thereby cause a loss of
residual renal function (RRF). When treating podocytes with the
vitamin B1 analog benfotiamine, damage mediated by high glu-
cose and peritoneal dialysis (PD) fluids is reduced, in particular,
regarding cytoskeletal organization,motility, inflammation,as well
as podocyte survival; this might be an implication for preservation
of RRF in PD.
INTRODUCTION
Preservation of residual renal function (RRF) contributes signifi-
cantly to an improved survival of patients undergoing peritoneal
dialysis (PD) (1–3). Several studies have tried to identify potential
risk factors for the decline of RRF, but the underlying mecha-
nisms remain unknown. Glucose and glucose degradation prod-
ucts (GDP), present at higher concentrations in the peritoneal
dialysis fluid (PDF), have been shown to be a major mediator
of damage to the peritoneum (4–6). As a consequence of reab-
sorption, the effects of the PDFs are not limited to the peritoneal
cavity, and studies have shown that the kidneys are particularly
susceptible, leading to damage, and decreased RRF (7–11).
Glucose degradation products are a heterogeneous group of
small molecular weight carbonyls formed within PDFs as a direct
consequence of heat-sterilization (12). They exhibit a facile reac-
tivity with various biomolecules, including proteins, DNA, and
phospholipids, generating stable products, such as advanced gly-
cation end-products (AGEs). An accumulation of AGEs has been
shown to contribute to the pathogenesis of vascular diseases,
such as atherosclerosis and diabetes (13). Furthermore, AGE-
modified proteins have also been shown to interact and activate
the receptor for AGE (RAGE), leading to an NFκB dependent pro-
inflammatory response. It could be demonstrated that blocking
of AGE/RAGE interactions in podocytes, using an anti-human
RAGE body, was able to prevent GDP-induced inflammation (14).
Although effective in vitro, the use of blocking antibodies in vivo
and particularly as a clinical treatment option is imperfect.
An alternative strategy would be to reduce the burden of
the high glucose and GDP content in PDFs through acti-
vation of innate defensive metabolic pathways, such as the
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pentose-phosphate pathway. It has been demonstrated that the
peritoneal membrane can be protected against PDF-induced dam-
age by high glucose, by treatment with benfotiamine, an analogy
of thiamine, and cofactor for transketolase (TKT). Increased TKT
activity, in vitro and in vivo, has been shown to be effective in
reducing the accumulation of the triosesphosphate intermediates
(glyceraldeyhde-3-phosphate and dihydroxyacetone phosphate),
by activation of the pentose-phosphate pathway, shifting glycolytic
flux into the formation of ribose-5-phosphate and NADPH.
Reducing the accumulation of the triosesphosphate pool, prevents
the activation of the classical biochemical pathways responsible
for cellular dysfunction observed in hyperglycemia, such as the
increased de novo synthesis of diacylglycerol and activation of
protein kinase C (PKC); oxidative stress linked to mitochondr-
ial dysfunction; activation of the hexosamine pathway, and the
increased formation of methylglyoxal (MG) and AGEs (9).
The purpose of the study was to investigate the effects of ben-
fotiamine to glucose and PDF in preventing cellular dysfunction
in podocytes.
MATERIALS AND METHODS
CELL CULTURE OF PODOCYTES
The conditionally immortalized human podocyte cell line AB8/13
was cultured as described elsewhere (15). In brief, podocytes were
maintained in RPMI-1640 medium supplemented with 10% fetal
calf serum (FCS; Gibco-BRL, Gaithersburg, MD, USA), 100 U/mL
penicillin, 100 mg/mL streptomycin, 1% insulin–transferrin–
selenium liquid media supplement (Sigma-Aldrich, Taufkirchen,
Germany), and 10 IU/mL recombinant mouse interferon-γ (Cell
Sciences, Canton, MA, USA) at 33°C (permissive conditions).
To induce differentiation, podocytes were cultured at 37°C with-
out interferon-γ (non-permissive conditions). After 14 days under
non-permissive conditions, cells had an arborous shape and
expressed synaptopodin and podocin, as determined by immuno-
fluorescence or western blot analysis (Data not shown). Passages
between 5 and 15 were used in this study.
INCUBATION OF PODOCYTES WITH HIGH GLUCOSE, PDF, AND
BENFOTIAMINE
Differentiated podocytes, grown on type I collagen coated plates,
were starved in RPMI containing 0.5% FCS for 24 h. The cells were
then treated with high glucose (glucose) or PDF for 48 h. High glu-
cose concentration was 2.5%; as PDF, the 2.5% glucose containing
Gambrosol Trio 10 (GambroCorporate Research, Hechingen, Ger-
many) was used. All experiments were repeated at least three times
in each indicated condition. Glucose and PDF were used for incu-
bation in a ratio with respect to cell culture medium 1+ 1 (9,14,16,
17). For control stimulations, cells were treated with a buffer-only
compartment of the PDF, contenting no glucose (kindly provided
by Gambro, Lundia, Sweden). Cells were co-stimulated with or
without benfotiamine (WörwagPharma, Böblingen, Germany),
to final concentration of 50µM as performed before (9, 13). To
exclude different protein content due to different number of cells
after incubation with glucose and PDF, we measured the protein
content of cell lysates of all groups using PierceBCA Protein Assay
Kit (Thermo Scientific, Langenselbold, Germany) according to the
manufacturer’s instructions.
IMMUNOFLUORESCENCE
Following stimulation, cells were either fixed with methanol
or 3% paraformaldehyde phosphate-buffered saline (PBS) for
15 min, permeabilized with 0.2% Triton X-100 for 5 min, and
incubated with primary antibodies and appropriate fluores-
cently labeled secondary antibodies in blocking solution (2%
bovine serum albumin, 2% FCS, and 0.2% fish gelatine in
PBS). For nuclear staining and detection of fragmented apop-
totic nuclei, fixated cells were stained with 0.1 mg/mL Hoechst
33342 (Invitrogen, Karlsruhe, Germany), which was included
with the secondary antibody. Antibodies directed against the
following proteins were used: anti-AGE (rabbit polyclonal IgG,
BioLogo, Kronshagen, Germany), anti-synaptopodin (P-19) (goat
polyclonal IgG), anti-podocin (H-130) (rabbit polyclonal IgG),
anti-nuclear factor kappa B (NFκB) P65 (rabbit polyclonal IgG,
Santa Cruz Biotechnology, Heidelberg, Germany), and anti-zonula
occludens-1 (ZO-1) (rabbit polyclonal IgG, Invitrogen, Karl-
sruhe, Germany). With the exception of the anti-phalloidinIgG
(Sigma-Aldrich, Deisenhofen, Germany), which was directly
conjugated to fluorescein isothiocyanate (FITC), for antigen–
antibody complexes were visualized with DyLight 488- and
Cy3-conjugated secondary antibodies (Dianova, Hamburg, Ger-
many). Negative control was performed by using PBS instead of
primary antibody.
To investigate AGE expression, a semiquantitative analysis was
carried out using a score system of 0–4 (0= no signal to 4= strong
signal). For analysis of actin cytoskeleton organization, the num-
ber of cells, which revealed a cortical reorganization of the actin
cytoskeleton, was counted, and the total cell number was set to
100%. For analysis of NFκB–p65 activation, a positive signal,
which co-localized with the nucleus, was counted, and the total
cell number set to 100%. Localization of podocin within the
cell was analyzed using a scoring system that comprises mem-
brane/cytoplasmic pattern (score 0), beginning reorganization to
perinuclear or nuclear envelope (score= 1), and perinuclear or
nuclear envelope (score= 2). Apoptosis was examined by Hoechst-
stained fragmented nuclei or apoptotic bodies,percentage of apop-
totic cells were assessed, control− benfotiamine was set zero and
fold change shown.
Images were taken using a Nikon DS-Qi1Mc quantitative black-
and-white charge-coupled device camera attached to a Nikon
Eclipse 80i upright microscope (Nikon, Düsseldorf, Germany).
The same contrast and intensity settings were applied to samples
stained with identical antibodies (9, 14, 18, 19).
WESTERN BLOT ANALYSIS
Following stimulation, podocytes were lysed, protein con-
centration was assessed by Pierce BCA Protein Assay Kit
(Thermo Scientific, Langenselbold, Germany) and after being
boiled in sodium dodecyl sulfate (SDS) sample buffer, 5–
20µg of lysate was separated by 8–12% SDS-polyacrylamide
gel electrophoresis and transferred to a nitrocellulose mem-
brane. The following antibodies were used: anti-podocin (H-
130) (rabbit polyclonal IgG, Santa Cruz Biotechnology, Heidel-
berg, Germany) and anti-ZO-1 (rabbit polyclonal IgG, Invit-
rogen, Karlsruhe, Germany). Equal loading was verified by
the detection of tubulin with anti-α-tubulin (mAB IgG1,
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Sigma-Aldrich, Deisenhofen, Germany). Protein detection was
performed after the incubation with primary and peroxidase-
conjugated secondary antibodies using a Supersignal Pico detec-
tion kit (Pierce, Bonn, Germany) according to the manufacturer’s
instructions.
MIGRATION ASSAY
A scratch, using P200 tip was made within the monolayer of
differentiated podocytes and treated as described. Images were
taken immediately after wounding (0 h) and at 24 h after using
a motor-controlled inverse microscope system Nikon Eclipse
TE2000-E (Nikon, Düsseldorf, Germany). Analyses were per-
formed with NIS Elements AR 2.30 (Nikon, Düsseldorf, Germany)
by counting the number of cells that had migrated into the
sized fields (14, 19, 20). For statistical analysis, the wounded
area from each dish was measured in duplicates at six random
wound gap locations per frame recorded per experiment, and at
least four independent scratch-wound experiments were used for
calculations.
STATISTICAL ANALYSIS
All data are demonstrated as mean± SD of at least three indepen-
dent experiments unless otherwise specified. The Mann–Whitney
U -test was carried out to test statistical significance. The signif-
icance level was set at least at P < 0.05. The statistical analysis
was performed by PC-Statistik (version 5.0; Hoffmann, Giessen,




Immunofluorescence analysis revealed a stronger total AGE for-
mation in podocytes incubated with glucose or PDF. In contrast,
addition of benfotiamine resulted in decreased AGE formation
and deposition in podocytes (Figures 1A,B).
LOCALIZATION OF PODOCYTE SPECIFIC PROTEIN PODOCIN
It is known that mutations in the podocin gene NPHS2
cause nephrotic syndrome that is accompanied by proteinuria
(21). Here, we found a relocalization of podocin protein after
incubation of glucose and PDF without benfotiamine. These
groups exhibited significantly more cells localized perinuclearly
or to the nuclear envelope in comparison to when benfoti-
amine was added and as compared to control cells (score:
glucose: 0.53± 0.24 versus glucose+ benfotiamine: 0.30± 0.19,
P < 0.01; PDF: 0.43± 0.27 versus PDF+ benfotiamine: 0.26±
0.18, P < 0.05, Figures 2A,B).
LOCALIZATION OF ZONULA OCCLUDENS PROTEIN-1
To investigate localization of tight junction-associated protein
ZO-1 an immunofluorescence analysis was performed. It is known
that in differentiated podocytes ZO-1 localizes to sites of cell–
cell contacts between interdigitating processes (22). There was
decreased ZO-1 localization at sites of cell–cell contact in the
glucose and PDF group; in the presence of benfotiamine, a nor-
mal distribution of ZO-1 at the cell–cell contacts was maintained
(Figure 3).
FIGURE 1 | AGE expression. Immunofluorescence staining of podocytes
to investigate the effect of ±benfotiamine after 48 h of incubation on the
expression of AGE in the control, glucose, and PDF group. Highest AGE
expression was found in the glucose and PDF group without benfotiamine;
scale bar represents 50µm (A). Quantitation of the AGE expression,
highest AGE expression was present in the glucose and PDF group without
benfotiamine (B). #P <0.05 versus −benfotiamine. AGE, advanced
glycation end-products; PDF, peritoneal dialysis fluid.
ACTIN CYTOSKELETON
The preservation of the actin cytoskeleton is important to main-
tain morphology and function of podocytes. Actin fiber sta-
tus can be analyzed with respect to normal well-developed
podocyte stress fibers or a reorganized cortical actin fiber phe-
notype (14, 23). For this, immunofluorescence staining of phal-
loidin was conducted. In our experiments, the control group
(±benfotiamine) showed well-developed stress fibers whereas
a distinct increase in rearranged fibers could be found in
the glucose and PDF group without benfotiamine. Here, we
observed a cortical actin fiber phenotype. In contrast, addi-
tion of benfotiamine resulted in a significant increase of normal
stress fibers, although not reaching control level (glucose: 41.0
± 9.31% versus glucose+ benfotiamine: 56.0± 8.04%, P < 0.05;
PDF: 45.2± 10.3% versus PDF+ benfotiamine: 62.69± 5.00%,
P < 0.05, Figures 4A,B).
MIGRATION ASSAY
The wound was closed best in the control groups (±benfotiamine).
In contrast, in the glucose and PDF (−benfotiamine)
migration was significantly reduced, whereas when benfo-
tiamine was present, motility was augmented to control
level (migrated cells – % of control: glucose: 87.1± 10.3%
versus glucose+ benfotiamine: 110± 17.2%, P < 0.05; PDF:
66.8± 13.2% versus PDF+ benfotiamine: 107± 13.8%, P < 0.05,
Figures 5A,B).
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FIGURE 2 | Localization of podocin. Immunofluorescence staining of
podocytes to investigate the effect of ±benfotiamine after 48 h of
incubation on the localization of podocin in the control, glucose, and PDF
group. Highest relocalization score was observable in the glucose and PDF
group without benfotiamine. Representative images of podocin staining
(Dylight488), upper panel, and a merge of podocin and nuclei (Hoechst),
lower panel, scale bar represents 50µm (A), quantitation of the
relocalization of podocin (B). ##P <0.01 versus −benfotiamine, §P < 0.05
versus −benfotiamine. PDF, peritoneal dialysis fluid.
INFLAMMATION – NFκB ACTIVATION
Higher numbers of NFκB activated cells shown by nuclear NFκB
expression could be observed in the glucose and PDF group
compared to control. This NFκB activation was reduced when
benfotiamine had been added (glucose: 8.93± 5.26% versus glu-
cose+ benfotiamine: 2.72± 1.21%, P < 0.05; PDF: 6.01± 4.60%
versus PDF+ benfotiamine: 3.66± 5.17%, Figures 6A,B).
APOPTOSIS
This morphological analysis revealed about twofold higher apop-
tosis in the glucose group and the PDF group in comparison
to control. When benfotiamine had been added apoptosis rates
were significantly reduced in both groups (fold control: glucose:
2.25± 0.34 versus glucose+ benfotiamine: 1.10± 0.26, P < 0.05;
PDF: 1.86± 0.17 versus PDF+ benfotiamine: 0.71± 0.34%,
P < 0.05, Figure 7).
FIGURE 3 | Localization of zonula occludens protein-1.
Immunofluorescence staining of podocytes to investigate the effect of
±benfotiamine after 48 h of incubation on the localization of ZO-1 in the
control, glucose, and PDF group. Highest relocalization was observable in
the glucose and PDF group without benfotiamine. Representative images
of ZO-1 staining, scale bar represents 50µm; arrows show normal
localization of ZO-1; arrow heads show mislocalized/absent of ZO-1. ZO-1,
zonula occulens-1; PDF, peritoneal dialysis fluid; C, control group; C+B,
control group+benfotiamine; G, glucose group; G+B, glucose
group+benfotiamine; P, PDF group; P+B, PDF group+benfotiamine.
DISCUSSION
During PD, exposure to high glucose and GDP-containing PDF
are the causative agents leading to peritoneal and systemic toxi-
city (4, 5, 8, 24). Although clinical studies failed to identify high
GDP-containing PDF as a valid risk factor contributable for the
decline of RRF in PD (25), animal studies support the hypothe-
sis that highly reactive GDP might be major mediators of renal
damage (8).
Within this context alternative therapeutic approaches to
reduce the burden of high glucose and GDP content in PDF are
of special interest. Many approaches have been taken to lower
the toxicity of PDF, such as blocking TGFβ1 or the administra-
tion of anti-fibrous drugs, such as rosiglitazone. Benfotiamine
has also been shown to be beneficial in this regard (9). Benfo-
tiamine is a thiamine monophosphate prodrug, which activates
the pentose-phosphate pathway by increasing the activity of TKT
(13, 26). It has been shown that expression of TKT is a critical fac-
tor in preventing hyperglycemia-induced metabolic dysfunction
in vitro (27). Activation of pentose-phosphate pathway not only
leads to NADPH production, which helps to sustain enzymatic
antioxidant defenses as well the metabolism of reactive metabo-
lites formed from oxidative and non-oxidative processes, but also
prevents the accumulation of fructose-6-phosphates and trios-
esphosphates, thereby preventing the activation of the hexamine
and PKC pathways, as well as mitochondrial dysfunction dri-
ven by the glycerophosphate shuttle and increased formation of
MG and MG-associated advanced glycation end-products (AGEs)
(13, 28).
As benfotiamine interferes into the glucose metabolism at an
early stage, by shifting glycolytic flux away from the accumulation
of triophosphates into the formation of ribose-5-phosphate (13,
26), it could potentially reduce podocyte toxicity, particularly as it
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FIGURE 4 | Actin cytoskeleton. Immunofluorescence staining of
podocytes to investigate the effect of ±benfotiamine after 48 h of
incubation on phalloidin in the control, glucose, and PDF group,
magnification 400 x (A). Quantitation of the organization of the actin
cytoskeleton, lowest percentage of normal stress fiber organization was
present in the glucose and PDF group without benfotiamine (B). #P<0.05
versus −benfotiamine, §P<0.05 versus −benfotiamine. PDF, peritoneal
dialysis fluid.
FIGURE 5 | Migration. Migration assay to investigate the effect of
±benfotiamine after 48 h of incubation on podocyte motility in the control,
glucose, and PDF group, phase contrast microscopy, scale bar represents
200µm (A). Quantitation of migration, lowest motility was found in the
glucose and PDF group without benfotiamine (B). #P<0.05 versus
−benfotiamine, §P<0.05 versus −benfotiamine. PDF, peritoneal dialysis fluid.
has been shown that glucose and PDF enter the systemic circula-
tion and thereby cause podocyte damage (7, 8, 14). The purpose
of our study was to investigate the potential beneficial effects of
benfotiamine to podocyte dysfunction during PD; therefore, we
cultured human podocytes and incubated them with glucose and
PDF in the absence and presence of benfotiamine. It was shown
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FIGURE 6 | Inflammation – NFκB activation. Immunofluorescence
staining of podocytes to investigate the effect of ±benfotiamine after 48 h of
incubation on inflammation in the control, glucose, and PDF group,
representative images of NFκB–P65 staining, (Cy3) upper panel, and a
merge of NFκB and nuclei (Hoechst), lower panel, scale bar represents
50µm (A). Quantitation of NFκB activated cells, highest percentage of NFκB
activation was present in the glucose and PDF group without benfotiamine
(B). #P< 0.05 versus −benfotiamine. NFκB, nuclear factor kappa B; PDF,
peritoneal dialysis fluid.
FIGURE 7 | Apoptosis. Analysis of apoptosis in podocytes to investigate
the effect of ±benfotiamine after 48 h of incubation in the control, glucose,
and PDF group. Apoptosis was detected by fragmented nuclei and was
highest in the glucose and PDF group. #P <0.05 versus −benfotiamine,
§P <0.05 versus −benfotiamine.
that treatment with high glucose and/or GDP-containing PDF
increased AGE formation, as well relocalization of proteins such
as podocin protein to the perinucleus and/or nuclear envelope;
decreased ZO-1 from sites of cell–cell contact and reorganization
of actin cytoskeleton to a cortical fiber phenotype. These changes
were associated with decreased cell migration, increased activation
of NFκB, and increased apoptosis. These observed effects were
reduced by co-treatment with benfotiamine.
Although no direct measurements of TKT activity or the
pentose-phosphate pathway were made, the observed reduction
in AGE formation and deposition would tend to suggest that the
beneficial effects observed are likely due to the activation of the
pentose-phosphate pathway. Further studies would be required to
confirm this. These findings also would suggest within the context
of PD that use of benfotiamine would be an effective therapeutic
option for reducing the toxic effects of PDF (9) and preserving
RRF; however, its usefulness would be limited to only addressing
the direct effects of high glucose from PDF and not the effects of
the high toxic GDPs, which are also present at high concentrations.
Studies have shown that the toxic effects of GDPs can be
reduced by supplementing PDFs with either scavengers of GDPs,
such as aminoguanidine, or antioxidants, such as glutathione. Fur-
thermore, it has also been shown that blocking of the RAGE can
prevent GDP-induced cellular damage in podocytes incubated
with PDF (14). Therefore, any new therapeutic treatments to pre-
serve RRF in PD patients would need to target not only the effects
of high glucose but also the effects of GDPs. This is supported
by clinical studies, which have failed to show a clear association
between declining RRF in PD and glucose or GDP content of
the PDFs.
Further in vitro and in vivo studies would be required to estab-
lish whether a treatment with benfotiamine or in combination
with either antioxidants and/or scavengers of GDPs would be an
effective approach to reducing the toxic effects of PDF. Especially
in clinical studies, we plan to proof our hypothesis, as benfoti-
amine is a vitamin B1 analog that might be an applicable drug to
be administered to patients with negligible side effects to prevent
local and systemic damage in PD.
CONCLUSION
The findings of this study suggest that treatment with benfo-
tiamine can reduce the toxic effects of PDFs, in particularly
those affects resulting from high glucose. Further experimental
and clinical studies are required to validate whether treatment
with benfotiamine would be of therapeutic benefit to patients
undergoing PD.
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